BCAB vs. LENZ, OMGA, VCXB, GRPH, GNFT, INMB, CLLS, CADL, AGEN, and MOLN
Should you be buying BioAtla stock or one of its competitors? The main competitors of BioAtla include LENZ Therapeutics (LENZ), Omega Therapeutics (OMGA), 10X Capital Venture Acquisition Corp. III (VCXB), Graphite Bio (GRPH), Genfit (GNFT), INmune Bio (INMB), Cellectis (CLLS), Candel Therapeutics (CADL), Agenus (AGEN), and Molecular Partners (MOLN). These companies are all part of the "biological products, except diagnostic" industry.
LENZ Therapeutics (NASDAQ:LENZ) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation, institutional ownership and community ranking.
LENZ Therapeutics has a beta of 0.2, suggesting that its stock price is 80% less volatile than the S&P 500. Comparatively, BioAtla has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500.
54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 38.4% of LENZ Therapeutics shares are held by company insiders. Comparatively, 8.4% of BioAtla shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
LENZ Therapeutics currently has a consensus target price of $31.33, suggesting a potential upside of 77.02%. BioAtla has a consensus target price of $11.00, suggesting a potential upside of 334.78%. Given LENZ Therapeutics' higher probable upside, analysts clearly believe BioAtla is more favorable than LENZ Therapeutics.
BioAtla's return on equity of -33.12% beat LENZ Therapeutics' return on equity.
BioAtla received 17 more outperform votes than LENZ Therapeutics when rated by MarketBeat users. However, 100.00% of users gave LENZ Therapeutics an outperform vote while only 66.67% of users gave BioAtla an outperform vote.
BioAtla has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.
In the previous week, LENZ Therapeutics had 10 more articles in the media than BioAtla. MarketBeat recorded 12 mentions for LENZ Therapeutics and 2 mentions for BioAtla. LENZ Therapeutics' average media sentiment score of 0.96 beat BioAtla's score of 0.40 indicating that BioAtla is being referred to more favorably in the news media.
Summary
BioAtla beats LENZ Therapeutics on 9 of the 15 factors compared between the two stocks.
Get BioAtla News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
